Kellie-Marie Banks

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

Ailsa J. Frew, Ralph K. Lindemann, Ben P. Martin et al. · Proceedings of the National Academy of Sciences · 2008 · 148 citations · Full text

Medicine, Oncology, Pharmacology +17

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

Michaela Waibel, Vanessa S. Solomon, Deborah A. Knight et al. · Cell Reports · 2013 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

Ailsa J. Christiansen, Alison C. West, Kellie-Marie Banks et al. · Proceedings of the National Academy of Sciences · 2011 · 114 citations

Medicine, Immunology, Oncology +17

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

Kate F. Whitecross, Amber E. Alsop, Leonie A. Cluse et al. · Blood · 2008 · 81 citations · Full text

Medicine, Oncology, Pharmacology +16

Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737

Adrian P. Wiegmans, Amber E. Alsop, Michael Bots et al. · Cancer Research · 2011 · 53 citations · Full text

Life Sciences, Oncology, Pharmacology +17